ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,496,678 | -31.6% | 182,235 | -11.5% | 0.03% | -27.7% |
| Q2 2023 | $9,504,210 | +14.0% | 206,031 | -0.9% | 0.05% | +4.4% |
| Q1 2023 | $8,335,106 | -21.8% | 207,858 | -9.7% | 0.04% | -26.2% |
| Q4 2022 | $10,664,888 | +36.7% | 230,194 | +22.2% | 0.06% | +19.6% |
| Q3 2022 | $7,803,000 | +301.4% | 188,421 | +478.3% | 0.05% | +325.0% |
| Q2 2022 | $1,944,000 | +764.0% | 32,581 | +1282.3% | 0.01% | +1100.0% |
| Q2 2021 | $225,000 | -87.2% | 2,357 | -84.8% | 0.00% | -90.0% |
| Q1 2021 | $1,761,000 | +383.8% | 15,466 | +489.0% | 0.01% | +400.0% |
| Q4 2020 | $364,000 | -6.4% | 2,626 | -30.9% | 0.00% | -50.0% |
| Q2 2015 | $389,000 | +18.2% | 3,800 | -28.3% | 0.00% | +33.3% |
| Q1 2015 | $329,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |